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Background
Methylene blue (MB) is lately being proposed to be effective
in treating Alzheimer’s disease (AD). Phase 2 clinical trials
reported improvements in cognitive functions of AD
patients after MB treatment. One of the main mechanisms
of action that has been described for MB is inhibition of Tau
aggregation [1]. Moreover, its antioxidant and mitochondrial
protection have been previously described [2]. Only recently,
a study using a triple transgenic AD mouse model has tested
the mechanism of MB in vivo, showing improved cognition
and reduced Ab levels after MB treatment [3].
Recently, the mitochondrial enzyme Amyloid binding
alcohol dehydrogenase (ABAD) has been shown to bind
Ab inducing mitochondrial dysfunction, providing a direct
relation between Ab and mitochondrial dysfunction occur-
ring in AD. Previous studies have shown that inhibiting
ABAD protects mitochondrial functions and prevented
Ab-induced toxicity [4][5]. Taking into consideration the
mitochondrial protective effect of MB and the recent data
suggesting its ability to reduce Ab levels, our aim was to
investigate the effect of MB on ABAD and mitochondrial
function in an LPS mouse model that has been previously
described to induce memory impairment, with Ab accu-
mulation in hippocampus and cerebral cortex [6].
Materials and methods
LPS mouse model was used (I.P 250 µg/kg LPS for 7 con-
secutive days) and accumulation of Ab was assessed by
immunohistochemistry. To Test the effect of MB on this
in vivo model, mice were treated for 4 days with MB (I.P 4
mg/kg). After sacrification of the mice, mitochondrial
associated ROS and cell viability of brain cells were mea-
sured using dihydrorhodamine probe and MTT assay
respectively. Moreover, ABAD and Ab levels were deter-
mined by western blotting in the brains of the treated
mice compared to the control group.
Results
The LPS mouse model used in this study showed brain
accumulation of Ab, decreased cell viability and increased
mitochondrial associated ROS levels compared to the
vehicle group. MB treatment significantly increased cell
viability and reduced the LPS-induced increase in the
ROS level. Moreover, brain Ab level of the MB treated
group was significantly decreased compared to the
untreated group. Most interestingly, MB treatment was
able to reduce the high level of ABAD that was found in
the LPS mouse model.
Conclusions
Taken together our results showed that MB decreased both
Ab and ABAD levels, while protecting the mitochondria
from oxidative stress, consequently improving brain cell via-
bility. Based on the previously reported role of the interac-
tion between ABAD and AB in inducing mitochondrial
dysfunction, the current study suggests a novel mechanism
of action of MB, linking its mitochondrial protective effects
to its lowering effect of both AB and ABAD which may
decrease their binding and the resultant mitochondrial
stress.
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